Bourauel Leonie

Clinical outcomes of the PAUL glaucoma implant in primary open-angle and pseudoexfoliative glaucoma eyes after failed glaucoma surgeries.

In conclusion, the PGI demonstrated significant IOP reduction and decreased need for medication in both POAG and PEXG patients, with no major differences between the two groups at 12 months.

Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.

PGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.

Comparing the use of Tutopatch® pericardium with Tutoplast® fascia lata in the context of PAUL® glaucoma implant surgery: an anterior segment OCT study.

This study shows that AS-OCT is a useful method for comparing different patch materials after PGI surgery.

Clinical Outcomes of Intraluminal Stent Removal After PAUL Glaucoma Implant Surgery.

Removal of the prolene stent following PGI surgery effectively lowers IOP in the short term, with a moderate increase in IOP and need for pressure-lowering therapy over time.